Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questions
Top Cited Papers
- 29 April 2004
- journal article
- research article
- Published by Wiley in Health Economics
- Vol. 13 (5), 405-415
- https://doi.org/10.1002/hec.903
Abstract
Cost-effectiveness acceptability curves (CEACs) have been widely adopted as a method to quantify and graphically represent uncertainty in economic evaluation studies of health-care technologies. However, there remain some common fallacies regarding the nature and shape of CEACs that largely result from the ‘textbook’ illustration of the CEAC. This ‘textbook’ CEAC shows a smooth curve starting at probability 0, with an asymptote to 1 for higher money values of the health outcome (λ). But this familiar ‘ogive’ shape which makes the ‘textbook’ CEAC look like a cumulative distribution function is just one special case of the CEAC. The reality is that the CEAC can take many shapes and turns because it is a graphic transformation from the cost-effectiveness plane, where the joint density of incremental costs and effects may ‘straddle’ quadrants with attendant discontinuities and asymptotes. In fact CEACs: (i) do not have to cut the y-axis at 0; (ii) do not have to asymptote to 1; (iii) are not always monotonically increasing in λ; and (iv) do not represent cumulative distribution functions (cdfs). Within this paper we present a ‘gallery’ of CEACs in order to identify the fallacies and illustrate the facts surrounding the CEAC. The aim of the paper is to serve as a reference tool to accompany the increased use of CEACs within major medical journals. Copyright © 2004 John Wiley & Sons, Ltd.Keywords
This publication has 32 references indexed in Scilit:
- Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approachPsychological Medicine, 2003
- Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analysesBMJ, 2003
- Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis * Commentary: Evaluating disease modifying treatments in multiple sclerosisBMJ, 2003
- The Cost-Effectiveness of Acetaminophen, NSAIDs, and Selective COX-2 Inhibitors in the Treatment of Symptomatic Knee OsteoarthritisValue in Health, 2003
- COUNSELING VERSUS ANTIDEPRESSANT THERAPY FOR THE TREATMENT OF MILD TO MODERATE DEPRESSION IN PRIMARY CAREInternational Journal of Technology Assessment in Health Care, 2003
- Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trialBMJ, 2002
- An Economic Evaluation of Activated Protein C Treatment for Severe SepsisNew England Journal of Medicine, 2002
- Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for HeartburnValue in Health, 2002
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994
- The CE PlaneMedical Decision Making, 1990